摘要
目的:观察拉米夫定加苦参素联合治疗慢性乙型肝炎的疗效及对慢性乙型肝炎病毒P基因(YMDD)变异的影响。方法:收集乙型肝炎病毒(HBV)HBeAg、HBVDNA阳性的慢性乙型肝炎患者67例,分为拉米夫定加用苦参素组(A组)、单用拉米夫定组(B组)。分别检测血清HBeAg、抗-HBe、HBVDNA、肝脏生化指标和基因YMDD变异。结果:在治疗56周时,拉米夫定联合苦参素组HBeAg/抗-HBe转换率(39.4%)优于拉米夫定组(P<0.05)。HBVDNA阳性率及YMDD变异率都比拉夫米定组低(P<0.05)。结论:拉米夫定联合苦参素能在一定程度上提高治疗慢性乙型肝炎的疗效并可减少YMDD变异。
Objetive：To observe the effect of combined application of lamivudine and oxymatrine in treating patients with chronic hepatitis B（CHB）and its influence on YMDD motif.Methods：67 patients of CHB with positive HBeAg and HBVDNA were divided into two groups. Group A was treated with lamivudine plus oxtmatrine,group B treated with lamivudine,the serum HBeAg/anti-HBe.HBVDNA,hepatic biological parameters and YMDD motif mutation were positive rate of HBeAg/anti-HBe（39.4%）in group A was higher than these in group B（P〈0.05）,the positive rate of HBVDNA and YMDD motif mutation in group A was were lower than those in group B respectively after 56 weeks treatment. Condusion：Combined application of lamivudine and oxtmatrine could enhance the therapeutic efficacy in treating CHB to some extent and reduce the mutation of YMDD motif.
出处
《中国医药导报》
CAS
2007年第04Z期24-25,共2页
China Medical Herald
